CME Company Insiders
CME Stock | USD 212.57 4.20 1.94% |
About 69% of CME's corporate insiders are selling. The analysis of the overall insider sentiment regarding CME Group suggests that many insiders are alarmed. CME employs about 3.6 K people. The company is managed by 63 executives with a total tenure of roughly 632 years, averaging almost 10.0 years of service per executive, having 56.59 employees per reported executive.
Cees Vermaas CEO Managing Director & CEO of CME Europe Limited |
Phupinder Gill CEO CEO, Director, Member of Competitive Markets Advisory Council, Member of Executive Committee and Member of Strategic Steering Committee |
CME's Insider Buying Vs Selling
31
Selling | Buying |
Latest Trades
2024-03-26 | William R Shepard | Acquired 12 @ 214.71 | View | ||
2024-01-31 | Timothy Francis Mccourt | Disposed 35 @ 206.78 | View | ||
2024-01-23 | Kathy E. Manning | Acquired @ 203.97 | |||
2024-01-18 | William R Shepard | Acquired 59 @ 202.44 | View | ||
2024-01-17 | Thomas R. Carper | Acquired @ 202.97 | |||
2023-12-28 | William R Shepard | Acquired 12 @ 210.79 | View | ||
2023-12-11 | Bryan T Durkin | Disposed 5560 @ 216.37 | View | ||
2023-12-06 | Michael C. Burgess | Disposed @ 214.25 | |||
2023-12-04 | Derek Sammann | Disposed 1862 @ 222.07 | View | ||
2023-12-01 | Derek Sammann | Disposed 10681 @ 220.5 | View | ||
2023-11-06 | Dennis Suskind | Disposed 1500 @ 213.6 | View | ||
2023-10-31 | Timothy Francis Mccourt | Disposed 43 @ 213.18 | View | ||
2023-10-30 | Elizabeth A Cook | Disposed 500 @ 211.43 | View | ||
2023-10-26 | Timothy Francis Mccourt | Disposed 1043 @ 216.37 | View | ||
2023-09-27 | William R Shepard | Acquired 12 @ 199.84 | View | ||
2023-08-18 | Terrence A Duffy | Disposed 30000 @ 203.95 | View | ||
2023-08-15 | Julie Holzrichter | Disposed 6000 @ 205.47 | View | ||
2023-08-11 | Timothy S Bitsberger | Disposed 800 @ 205.92 | View | ||
2023-08-10 | Julie Winkler | Disposed 6262 @ 207 | View |
Monitoring CME's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of CME's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of CME Group. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe CME's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
CME |
CME's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with CME's future performance. Based on our forecasts, it is anticipated that CME will maintain a workforce of about 3570 employees by May 2024.CME's latest congressional trading
Congressional trading in companies like CME Group, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in CME by those in governmental positions are based on the same information available to the general public.
2024-01-23 | Representative Kathy Manning | Acquired Under $15K | Verify | ||
2024-01-17 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
2023-12-06 | Representative Michael C. Burgess | Acquired $15K to $50K | Verify | ||
2023-05-25 | Representative Zoe Lofgren | Acquired Under $15K | Verify | ||
2023-01-31 | Representative Daniel Goldman | Acquired Under $15K | Verify | ||
2023-01-11 | Senator Thomas R. Carper | Acquired Under $15K | Verify | ||
2021-12-14 | Representative Robert J. Wittman | Acquired Under $15K | Verify | ||
2021-06-22 | Representative John Curtis | Acquired Under $15K | Verify | ||
2021-03-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
2020-09-23 | Representative Dean Phillips | Acquired Under $15K | Verify | ||
2020-09-04 | Representative Kurt Schrader | Disposed Under $15K | Verify | ||
2020-07-10 | Representative Donald S. Beyer, Jr. | Disposed Under $15K | Verify | ||
2020-07-01 | Representative John A. Yarmuth | Acquired Under $15K | Verify | ||
2020-03-19 | Senator Kelly Loeffler | Acquired $50K to $100K | Verify | ||
2020-02-20 | Representative Mikie Sherrill | Disposed Under $15K | Verify | ||
2019-03-11 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
2018-04-24 | Senator Shelley M Capito | Acquired $15K to $50K | Verify | ||
2017-01-05 | Representative Thomas Suozzi | Acquired Under $15K | Verify | ||
2014-07-23 | Senator Susan M Collins | Acquired Under $15K | Verify | ||
2014-07-23 | Senator Susan M. Collins | Acquired Under $15K | Verify |
CME Management Team Effectiveness
The company has Return on Asset of 0.0142 % which means that on every $100 spent on assets, it made $0.0142 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1203 %, implying that it generated $0.1203 on every 100 dollars invested. CME's management efficiency ratios could be used to measure how well CME manages its routine affairs as well as how well it operates its assets and liabilities. At present, CME's Return On Capital Employed is projected to increase slightly based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.03, whereas Return On Equity is forecasted to decline to 0.12. At present, CME's Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 99.6 B, whereas Other Assets are forecasted to decline to about 127.7 M.CME Quarterly Income Before Tax |
|
CME Workforce Comparison
CME Group is rated fifth in number of employees category among related companies. The total workforce of Financials industry is currently estimated at about 77,239. CME holds roughly 3,565 in number of employees claiming about 5% of equities under Financials industry.
CME Profit Margins
The company has Net Profit Margin of 0.58 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.62 %, which entails that for every 100 dollars of revenue, it generated $0.62 of operating income.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.92 | 0.8139 |
|
|
CME Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CME insiders, such as employees or executives, is commonly permitted as long as it does not rely on CME's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CME insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.7895 | 15 | 19 | 88,570 | 39,610 |
2023-12-01 | 0.2857 | 4 | 14 | 2,544 | 37,767 |
2023-09-01 | 0.4516 | 14 | 31 | 63,176 | 80,948 |
2023-03-01 | 1.6 | 8 | 5 | 5,739 | 2,021 |
2022-12-01 | 4.0 | 8 | 2 | 50,871 | 20,531 |
2022-09-01 | 0.303 | 10 | 33 | 59,369 | 25,508 |
2022-03-01 | 1.2727 | 42 | 33 | 38,691 | 51,059 |
2021-12-01 | 0.375 | 9 | 24 | 6,068 | 35,256 |
2021-09-01 | 0.2222 | 12 | 54 | 61,180 | 27,032 |
2021-06-01 | 1.75 | 21 | 12 | 13,401 | 49,520 |
2021-03-01 | 0.4828 | 14 | 29 | 125,536 | 95,895 |
2020-12-01 | 0.0526 | 1 | 19 | 2,500 | 51,489 |
2020-09-01 | 0.2143 | 12 | 56 | 68,100 | 46,497 |
2020-06-01 | 1.6429 | 23 | 14 | 19,322 | 15,701 |
2020-03-01 | 0.7273 | 32 | 44 | 166,550 | 91,851 |
2019-12-01 | 0.25 | 1 | 4 | 506.00 | 42,980 |
2019-09-01 | 0.2167 | 13 | 60 | 50,805 | 85,894 |
2019-06-01 | 0.8 | 28 | 35 | 50,440 | 88,671 |
2019-03-01 | 0.625 | 30 | 48 | 142,828 | 110,984 |
2018-12-01 | 0.3333 | 6 | 18 | 6,034,953 | 45,201 |
2018-09-01 | 0.6296 | 34 | 54 | 68,621 | 58,482 |
2018-06-01 | 1.4286 | 20 | 14 | 19,619 | 41,472 |
2018-03-01 | 0.6176 | 21 | 34 | 135,822 | 113,378 |
2017-12-01 | 0.2273 | 5 | 22 | 28,545 | 67,609 |
2017-09-01 | 0.4211 | 16 | 38 | 102,991 | 92,145 |
2017-06-01 | 1.0 | 34 | 34 | 60,596 | 76,359 |
2017-03-01 | 0.6 | 21 | 35 | 125,699 | 80,146 |
2016-12-01 | 0.3636 | 12 | 33 | 104,036 | 196,801 |
2016-09-01 | 0.3 | 21 | 70 | 152,253 | 167,853 |
2016-06-01 | 1.7647 | 30 | 17 | 82,734 | 121,365 |
2016-03-01 | 0.5833 | 21 | 36 | 171,257 | 106,729 |
2015-12-01 | 0.25 | 1 | 4 | 11,250 | 25,724 |
2015-09-01 | 0.3077 | 16 | 52 | 96,890 | 92,575 |
2015-06-01 | 1.2857 | 36 | 28 | 53,744 | 74,646 |
2015-03-01 | 0.4865 | 18 | 37 | 97,399 | 170,253 |
2014-12-01 | 0.4091 | 9 | 22 | 26,980 | 42,704 |
2014-09-01 | 0.6122 | 30 | 49 | 101,882 | 93,548 |
2014-06-01 | 3.75 | 15 | 4 | 64,750 | 100,000 |
2014-03-01 | 0.1667 | 4 | 24 | 33,694 | 68,577 |
2013-12-01 | 0.1765 | 3 | 17 | 22,525 | 37,257 |
2013-09-01 | 0.2128 | 10 | 47 | 59,072 | 40,645 |
2013-06-01 | 1.0556 | 19 | 18 | 60,521 | 86,185 |
2013-03-01 | 0.8824 | 15 | 17 | 70,116 | 64,354 |
2012-09-01 | 0.3333 | 12 | 36 | 73,870 | 38,329 |
2012-06-01 | 2.25 | 18 | 8 | 6,793 | 9,900 |
2012-03-01 | 0.8125 | 13 | 16 | 13,520 | 18,970 |
2011-12-01 | 1.0 | 2 | 2 | 319.00 | 90.00 |
2011-09-01 | 2.3333 | 21 | 9 | 32,797 | 11,643 |
2011-06-01 | 1.3571 | 19 | 14 | 4,988 | 6,016 |
2011-03-01 | 1.2 | 6 | 5 | 3,984 | 3,954 |
2010-12-01 | 0.2727 | 3 | 11 | 502.00 | 2,257 |
2010-09-01 | 2.1818 | 24 | 11 | 59,068 | 3,875 |
2010-06-01 | 1.3571 | 19 | 14 | 5,608 | 8,885 |
2010-03-01 | 0.4375 | 7 | 16 | 2,132 | 5,331 |
2009-12-01 | 0.3 | 3 | 10 | 893.00 | 8,623 |
2009-09-01 | 2.625 | 21 | 8 | 33,281 | 6,748 |
2009-06-01 | 0.5122 | 21 | 41 | 5,966 | 21,604 |
2009-03-01 | 7.0 | 7 | 1 | 1,495 | 100.00 |
2008-12-01 | 1.5 | 21 | 14 | 15,713 | 4,937 |
2008-09-01 | 4.0 | 4 | 1 | 46,359 | 48.00 |
2008-06-01 | 4.625 | 37 | 8 | 27,244 | 3,107 |
2008-03-01 | 0.6923 | 9 | 13 | 6,679 | 12,120 |
2007-12-01 | 0.4762 | 10 | 21 | 24,110 | 43,038 |
2007-09-01 | 1.0 | 30 | 30 | 78,722 | 19,450 |
2007-06-01 | 1.8333 | 33 | 18 | 26,291 | 15,165 |
2007-03-01 | 0.3913 | 9 | 23 | 7,960 | 29,240 |
2006-12-01 | 0.6875 | 11 | 16 | 24,685 | 40,690 |
2006-09-01 | 1.0 | 17 | 17 | 8,945 | 20,593 |
2006-06-01 | 1.5652 | 36 | 23 | 32,180 | 40,490 |
2006-03-01 | 0.3 | 12 | 40 | 13,301 | 34,619 |
2005-12-01 | 0.0884 | 13 | 147 | 31,950 | 68,900 |
2005-09-01 | 0.1212 | 8 | 66 | 10,600 | 47,648 |
2005-06-01 | 0.5077 | 33 | 65 | 28,817 | 50,277 |
2005-03-01 | 0.1429 | 7 | 49 | 9,500 | 23,299 |
2004-12-01 | 0.0435 | 2 | 46 | 17,000 | 58,000 |
2004-06-01 | 2.0 | 14 | 7 | 49,100 | 54,600 |
2004-03-01 | 1.3333 | 4 | 3 | 12,000 | 7,000 |
2003-12-01 | 0.5 | 6 | 12 | 53,800 | 113,490 |
2003-09-01 | 1.3333 | 4 | 3 | 101,683 | 112,733 |
2003-06-01 | 1.0 | 4 | 4 | 41,500 | 65,450 |
CME Notable Stakeholders
A CME stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CME often face trade-offs trying to please all of them. CME's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CME's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Cees Vermaas | Managing Director & CEO of CME Europe Limited | Profile | |
Phupinder Gill | CEO, Director, Member of Competitive Markets Advisory Council, Member of Executive Committee and Member of Strategic Steering Committee | Profile | |
Leo Melamed | Chairman Emeritus | Profile | |
Charles Carey | Vice Chairman of the Board | Profile | |
Terrence Duffy | Executive Chairman and President Member of Competitive Markets Advisory Council, Chairman of Executive Committee and Member of Strategic Steering Committee | Profile | |
Sunil Cutinho | President - CME Clearing | Profile | |
Kimberly Taylor | President of Global Operations, Technology and Risk | Profile | |
Ana Dutra | Independent Director | Profile | |
Daniel Glickman | Independent Director | Profile | |
Howard Siegel | Independent Director | Profile | |
Dennis Chookaszian | Independent Director | Profile | |
Steven Wollack | Independent Director | Profile | |
William Miller | Independent Director | Profile | |
Gedon Hertshten | Independent Director | Profile | |
Daniel Kaye | Director | Profile | |
Douglas Monieson | Independent Director | Profile | |
Jeffrey Bernacchi | Independent Director | Profile | |
James Oliff | Independent Director | Profile | |
Timothy Bitsberger | Independent Director | Profile | |
Patrick Maloney | Independent Director | Profile | |
Dennis Suskind | Independent Director | Profile | |
Alex Pollock | Lead Independent Director | Profile | |
David Wescott | Independent Director | Profile | |
Edemir Pinto | Independent Director | Profile | |
Deborah Lucas | Independent Director | Profile | |
John Sandner | Director | Profile | |
Larry Gerdes | Independent Director | Profile | |
Terry Savage | Independent Director | Profile | |
Bruce Johnson | Independent Director | Profile | |
Ronald Pankau | Independent Director | Profile | |
Yra Harris | Director | Profile | |
Michael Spencer | Director | Profile | |
Martin Gepsman | Independent Director | Profile | |
William Shepard | Independent Director | Profile | |
Kathleen Cronin | Senior Managing Director, General Counsel, Corporate Secretary | Profile | |
Derek Sammann | Senior Managing Director - Financial Products and Services | Profile | |
William Knottenbelt | Senior Managing Director, Europe, Middle East, Africa (EMEA) | Profile | |
John Pietrowhicz | Senior Managing Director - Business Development and Corporate Finance | Profile | |
Julie Holzrichter | COO and Sr. Managing Director | Profile | |
Bryan Durkin | Chief Commercial Officer and Sr. Managing Director | Profile | |
Hilda Piell | Chief Human Resource Officer, Senior Managing Director | Profile | |
Jack Tobin | Chief Accounting Officer, Managing Director | Profile | |
Linda Rich | Senior Managing Director - Government Relations and Legislative Affairs | Profile | |
Julie Winkler | Senior Managing Director - Research and Product Development | Profile | |
Kevin Kometer | CIO, Senior Managing Director | Profile | |
Robert Zagotta | Senior Managing Director - Products and Services | Profile | |
Jill Harley | Managing Director | Profile | |
Sean Tully | Senior Managing Director - Interest Rates, OTC Products | Profile | |
Kendal Vroman | Chief Officer | Profile | |
Michel Everaert | MD EMEA | Profile | |
Sean Keating | MD Office | Profile | |
Elizabeth Cook | Independent Trustee | Profile | |
Anita Liskey | Senior Communications | Profile | |
Jonathan Marcus | Senior Counsel | Profile | |
Lynne Fitzpatrick | Chief Officer | Profile | |
Edward Gogol | Managing Solutions | Profile | |
John Peschier | Managing Relations | Profile | |
Jason Weller | Managing Strategy | Profile | |
William Hobert | Independent Trustee | Profile | |
Christopher Bowen | Chief MD | Profile | |
Elizabeth Gisch | Managing Management | Profile | |
Eileen Keeve | Managing Devel | Profile | |
Kevin Lennon | Managing Estate | Profile |
About CME Management Performance
The success or failure of an entity such as CME Group often depends on how effective the management is. CME management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CME management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CME management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.03 | 0.06 | |
Return On Capital Employed | 0.09 | 0.17 | |
Return On Assets | 0.02 | 0.03 | |
Return On Equity | 0.12 | 0.12 |
The data published in CME's official financial statements usually reflect CME's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of CME Group. For example, before you start analyzing numbers published by CME accountants, it's critical to develop an understanding of what CME's liquidity, profitability, and earnings quality are in the context of the Capital Markets space in which it operates.
Please note, the presentation of CME's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CME's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in CME's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CME Group. Please utilize our Beneish M Score to check the likelihood of CME's management manipulating its earnings.
CME Workforce Analysis
Traditionally, organizations such as CME use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CME within its industry.CME Manpower Efficiency
Return on CME Manpower
Revenue Per Employee | 1.6M | |
Revenue Per Executive | 88.6M | |
Net Income Per Employee | 906K | |
Net Income Per Executive | 51.3M | |
Working Capital Per Employee | 413.3K | |
Working Capital Per Executive | 23.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CME Group. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for CME Stock analysis
When running CME's price analysis, check to measure CME's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CME is operating at the current time. Most of CME's value examination focuses on studying past and present price action to predict the probability of CME's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CME's price. Additionally, you may evaluate how the addition of CME to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum |
Is CME's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CME. If investors know CME will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CME listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.276 | Dividend Share 4.4 | Earnings Share 8.87 | Revenue Per Share 15.512 | Quarterly Revenue Growth 0.192 |
The market value of CME Group is measured differently than its book value, which is the value of CME that is recorded on the company's balance sheet. Investors also form their own opinion of CME's value that differs from its market value or its book value, called intrinsic value, which is CME's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CME's market value can be influenced by many factors that don't directly affect CME's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CME's value and its price as these two are different measures arrived at by different means. Investors typically determine if CME is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CME's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.